Literature DB >> 9593171

Susceptibilities of neonatal respiratory isolates of Ureaplasma urealyticum to antimicrobial agents.

A Matlow1, C Th'ng, D Kovach, P Quinn, M Dunn, E Wang.   

Abstract

Twenty-one neonatal respiratory isolates of Ureaplasma urealyticum were serotyped, and their susceptibilities to ciprofloxacin, gentamicin, chloramphenicol, erythromycin, azithromycin, and doxycycline were tested. Most patient strains were Ureaplasma urealyticum bv. parvum. Chloramphenicol, doxycycline, and azithromycin had the lowest MICs. This data may be useful when designing prophylactic or therapeutic trials of antibiotics for chronic lung disease of the newborn.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9593171      PMCID： PMC105810          DOI： 10.1128/AAC.42.5.1290

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

Review 1.  Mycoplasma infection of the fetus and newborn.

Authors:  P A Quinn
Journal:  Prog Clin Biol Res       Date:  1988

2.  Effect of pH, inoculum size, and incubation time on the susceptibility of Ureaplasma urealyticum to erythromycin in vitro.

Authors:  G E Kenny; F D Cartwright
Journal:  Clin Infect Dis       Date:  1993-08       Impact factor: 9.079

3.  Antibiotic susceptibilities and therapeutic options for Ureaplasma urealyticum infections in neonates.

Authors:  K B Waites; D T Crouse; G H Cassell
Journal:  Pediatr Infect Dis J       Date:  1992-01       Impact factor: 2.129

4.  Susceptibilities of Mycoplasma hominis and Ureaplasma urealyticum to two new quinolones, sparfloxacin and WIN 57273.

Authors:  G E Kenny; F D Cartwright
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

Review 5.  Current status of the mollicute flora of humans.

Authors:  J G Tully
Journal:  Clin Infect Dis       Date:  1993-08       Impact factor: 9.079

Review 6.  Therapeutic considerations for Ureaplasma urealyticum infections in neonates.

Authors:  K B Waites; D T Crouse; G H Cassell
Journal:  Clin Infect Dis       Date:  1993-08       Impact factor: 9.079

Review 7.  Ureaplasma urealyticum and chronic lung disease of prematurity: critical appraisal of the literature on causation.

Authors:  E E Wang; G H Cassell; P J Sánchez; J A Regan; N R Payne; P P Liu
Journal:  Clin Infect Dis       Date:  1993-08       Impact factor: 9.079

8.  Ureaplasma urealyticum colonization and chronic lung disease in low birth weight infants.

Authors:  P J Sánchez; J A Regan
Journal:  Pediatr Infect Dis J       Date:  1988-08       Impact factor: 2.129

Review 9.  Ureaplasma urealyticum intrauterine infection: role in prematurity and disease in newborns.

Authors:  G H Cassell; K B Waites; H L Watson; D T Crouse; R Harasawa
Journal:  Clin Microbiol Rev       Date:  1993-01       Impact factor: 26.132

10.  Ureaplasma urealyticum demonstrated by open lung biopsy in newborns with chronic lung disease.

Authors:  W F Walsh; S Stanley; K P Lally; R E Stribley; D P Treece; F McCleskey; D M Null
Journal:  Pediatr Infect Dis J       Date:  1991-11       Impact factor: 2.129
View more
  12 in total

1.  Ureaplasma urealyticum meningitis in an adult patient.

Authors:  Walter Geissdörfer; Günter Sandner; Stefan John; André Gessner; Christoph Schoerner; Klaus Schröppel
Journal:  J Clin Microbiol       Date:  2008-01-03       Impact factor: 5.948

2.  Azithromycin to prevent bronchopulmonary dysplasia in ureaplasma-infected preterm infants: pharmacokinetics, safety, microbial response, and clinical outcomes with a 20-milligram-per-kilogram single intravenous dose.

Authors:  Rose M Viscardi; Ahmed A Othman; Hazem E Hassan; Natalie D Eddington; Elias Abebe; Michael L Terrin; David A Kaufman; Ken B Waites
Journal:  Antimicrob Agents Chemother       Date:  2013-02-25       Impact factor: 5.191

3.  Pharmacokinetics, microbial response, and pulmonary outcomes of multidose intravenous azithromycin in preterm infants at risk for Ureaplasma respiratory colonization.

Authors:  L Marcela Merchan; Hazem E Hassan; Michael L Terrin; Ken B Waites; David A Kaufman; Namasivayam Ambalavanan; Pamela Donohue; Susan J Dulkerian; Robert Schelonka; Laurence S Magder; Sagar Shukla; Natalie D Eddington; Rose M Viscardi
Journal:  Antimicrob Agents Chemother       Date:  2014-11-10       Impact factor: 5.191

4.  Ureaplasma urealyticum biovar determination in women attending a family planning clinic in Guiné-Bissau, using polymerase chain reaction of the multiple-banded antigen gene.

Authors:  D Domingues; L Távora Tavira; A Duarte; A Sanca; E Prieto; F Exposto
Journal:  J Clin Lab Anal       Date:  2002       Impact factor: 2.352

Review 5.  Role of erythromycin for treatment of incipient chronic lung disease in preterm infants colonised with Ureaplasma urealyticum.

Authors:  C Bührer; T Hoehn; J Hentschel
Journal:  Drugs       Date:  2001       Impact factor: 9.546

6.  Concurrent titration and determination of antibiotic resistance in ureaplasma species with identification of novel point mutations in genes associated with resistance.

Authors:  Michael L Beeton; Victoria J Chalker; Nicola C Maxwell; Sailesh Kotecha; O Brad Spiller
Journal:  Antimicrob Agents Chemother       Date:  2009-03-09       Impact factor: 5.191

Review 7.  Role of Ureaplasma Respiratory Tract Colonization in Bronchopulmonary Dysplasia Pathogenesis: Current Concepts and Update.

Authors:  Rose Marie Viscardi; Suhas G Kallapur
Journal:  Clin Perinatol       Date:  2015-10-09       Impact factor: 3.430

8.  Maternal azithromycin therapy for Ureaplasma intraamniotic infection delays preterm delivery and reduces fetal lung injury in a primate model.

Authors:  Peta L Grigsby; Miles J Novy; Drew W Sadowsky; Terry K Morgan; Mary Long; Ed Acosta; Lynn B Duffy; Ken B Waites
Journal:  Am J Obstet Gynecol       Date:  2012-10-23       Impact factor: 8.661

9.  Does Ureaplasma spp. cause chronic lung disease of prematurity: ask the audience?

Authors:  Nicola C Maxwell; Diane Nuttall; Sailesh Kotecha
Journal:  Early Hum Dev       Date:  2009-01-13       Impact factor: 2.079

10.  Azithromycin in the extremely low birth weight infant for the prevention of bronchopulmonary dysplasia: a pilot study.

Authors:  Hubert O Ballard; Michael I Anstead; Lori A Shook
Journal:  Respir Res       Date:  2007-06-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.